As of 2024-12-11, the Relative Valuation of Relmada Therapeutics Inc (RLMD) is (68.94) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.47 USD, the upside of Relmada Therapeutics Inc based on Relative Valuation is -14775.1%.
The range of the Relative Valuation is (43.46) - (69.20) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.1x - 24.1x | 22.7x |
| Forward P/E multiples | 15.2x - 25.7x | 25.4x |
| Fair Price | (43.46) - (69.20) | (68.94) |
| Upside | -9350.5% - -14830.0% | -14775.1% |
| Date | P/E |
| 2024-12-06 | -0.16 |
| 2024-12-05 | -0.16 |
| 2024-12-04 | -0.22 |
| 2024-12-03 | -0.97 |
| 2024-12-02 | -1.15 |
| 2024-11-29 | -1.05 |
| 2024-11-27 | -1.01 |
| 2024-11-26 | -0.95 |
| 2024-11-25 | -0.96 |
| 2024-11-22 | -0.98 |
| 2024-11-21 | -0.96 |
| 2024-11-20 | -0.99 |
| 2024-11-19 | -1.04 |
| 2024-11-18 | -1.05 |
| 2024-11-15 | -1.05 |
| 2024-11-14 | -1.10 |
| 2024-11-13 | -1.12 |
| 2024-11-12 | -1.15 |
| 2024-11-11 | -1.13 |
| 2024-11-08 | -1.14 |
| 2024-11-07 | -1.14 |
| 2024-11-06 | -1.19 |
| 2024-11-05 | -1.16 |
| 2024-11-04 | -1.19 |
| 2024-11-01 | -1.22 |
| 2024-10-31 | -1.21 |
| 2024-10-30 | -1.22 |
| 2024-10-29 | -1.25 |
| 2024-10-28 | -1.27 |
| 2024-10-25 | -1.26 |
| 2024-10-24 | -1.27 |
| 2024-10-23 | -1.25 |
| 2024-10-22 | -1.27 |
| 2024-10-21 | -1.27 |
| 2024-10-18 | -1.26 |
| 2024-10-17 | -1.22 |
| 2024-10-16 | -1.22 |
| 2024-10-15 | -1.21 |
| 2024-10-14 | -1.17 |
| 2024-10-11 | -1.15 |
| 2024-10-10 | -1.16 |
| 2024-10-09 | -1.19 |
| 2024-10-08 | -1.22 |
| 2024-10-07 | -1.22 |
| 2024-10-04 | -1.21 |
| 2024-10-03 | -1.14 |
| 2024-10-02 | -1.19 |
| 2024-10-01 | -1.14 |
| 2024-09-30 | -1.13 |
| 2024-09-27 | -1.18 |